EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B. This Phase 1 study is designed primarily to assess Pharmacokinetics (PK) under fed and fasted conditions, and to assess the safety, tolerability and Pharmacodynamics (PD) of single oral doses of EYP001a in subjects with chronic HBV infection.
Epistemonikos ID: 2afeeb2affd75c118f914c5a2f2b1eabf96a9ece
First added on: Mar 23, 2020